- $120.95m
- $107.23m
- $2.04m
Humacyte rises over 40% on FDA approval for blood vessel implant
Brief: Humacyte Announces FDA Approval Of Symvess For The Treatment Of Extremity Vascular Trauma
Brief: Humacyte Announces Pricing Of $15.0 Million Registered Direct Offering
Humacyte Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Humacyte Q3 Operating Expenses USD 30.233 Million
Brief: Humacyte Announces Presentation Of Positive Results From V007 Phase 3 Av Access Clinical Trial At The American Society Of Nephrology’S Kidney Week 2024
Brief: Humacyte Inc Co, Lincoln Park Capital Fund, Llc Entered Purchase Agreement And Registration Rights Agreement
Humacyte Inc reports results for the quarter ended in June - Earnings Summary
Brief: Humacyte Q2 Operating Expenses USD 29.499 Million
U.S. STOCKS ON THE MOVE-Revance, B Riley, Neuronetics
U.S. STOCKS ON THE MOVE-Revance Therapeutics, B Riley Financial, KeyCorp
U.S. STOCKS ON THE MOVE-Interactive Strength, KeyCorp, Humacyte
Humacyte falls after US FDA extends review of co's blood vessel implant
US FDA extends review of Humacyte's blood vessel implant (updated)
US FDA extends review of Humacyte's blood vessel implant
Brief: Humacyte Acellular Tissue Engineered Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Patients With Advanced Peripheral Artery Disease
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
Humacyte Inc reports results for the quarter ended in March - Earnings Summary